<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medications other than alpha-1-receptor antagonists used to treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medications other than alpha-1-receptor antagonists used to treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medications other than alpha-1-receptor antagonists used to treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH)</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Pharmacologic class</td> <td class="subtitle1">Medication</td> <td class="subtitle1">Initial dose</td> <td class="subtitle1">Titration interval</td> <td class="subtitle1">Maximum dose</td> </tr> <tr class="divider_bottom"> <td>Phosphodiesterase-5 (PDE-5) inhibitor*</td> <td>Tadalafil (Cialis)</td> <td>5 mg daily</td> <td>None</td> <td>5 mg daily</td> </tr> <tr> <td class="divider_bottom" rowspan="2">5-alpha-reductase inhibitors (5-ARIs)<sup>¶</sup></td> <td>Finasteride (Proscar)</td> <td>5 mg daily</td> <td>None</td> <td>5 mg daily</td> </tr> <tr class="divider_bottom"> <td>Dutasteride (Avodart)</td> <td>0.5 mg daily</td> <td>None</td> <td>0.5 mg daily</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Beta-3 adrenergic agonists</td> <td>Mirabegron (Myrbetriq)</td> <td>25 mg daily</td> <td>May increase dose as needed and tolerated after ≥4 weeks</td> <td>50 mg daily</td> </tr> <tr class="divider_bottom"> <td>Vibegron (Gemtesa)</td> <td>75 mg daily</td> <td>None</td> <td>75 mg daily</td> </tr> <tr> <td rowspan="9">Anticholinergic agents<sup>Δ</sup></td> <td>Fesoterodine (Toviaz)</td> <td>4 mg daily</td> <td>May increase dose as needed and tolerated after ≥2 weeks</td> <td>8 mg daily</td> </tr> <tr> <td>Tolterodine IR (Detrol)</td> <td>1 to 2 mg twice daily</td> <td rowspan="2">None</td> <td>2 mg twice daily</td> </tr> <tr> <td>Tolterodine ER (Detrol LA)</td> <td>2 to 4 mg daily</td> <td>4 mg twice daily</td> </tr> <tr> <td>Oxybutynin IR (Ditropan<sup>◊</sup>)</td> <td>5 mg 2 to 3 times daily</td> <td rowspan="2">May increase dose as needed and tolerated in 5 mg increments every 1 to ≥2 weeks</td> <td>5 mg 4 times daily</td> </tr> <tr> <td>Oxybutynin ER (Ditropan XL)</td> <td>5 to 10 mg daily</td> <td>30 mg daily</td> </tr> <tr> <td>Darifenacin (Enablex)</td> <td>7.5 mg daily</td> <td rowspan="2">May increase dose as needed and tolerated after ≥2 weeks</td> <td>15 mg daily</td> </tr> <tr> <td>Solifenacin (Vesicare)</td> <td>5 mg daily</td> <td>10 mg daily</td> </tr> <tr> <td>Trospium IR (Sanctura<sup>◊</sup>)</td> <td>20 mg twice daily (once daily if &gt;75 years old)</td> <td rowspan="2">None</td> <td>20 mg twice daily</td> </tr> <tr> <td>Trospium ER (Sanctura XR<sup>◊</sup>)</td> <td>60 mg daily</td> <td>60 mg daily</td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Dosing recommendations are for oral administration in adult patients with normal organ function. For information on clinical use and individualizing drug selection according to predominant symptoms, refer to the clinical topic review of BPH and individual drug information topics included within UpToDate. For information on drug interactions, refer to the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> database.</li>
<li>Dosing recommendations for alpha-1-receptor antagonists used to treat lower urinary tract symptoms due to BPH are available in a separate table within UpToDate.</li>
</ul></div><div class="graphic_footnotes"><p>IR: immediate-release; ER: extended-release.</p>
<p>* PDE-5 inhibitors are a useful choice in men with erectile dysfunction. Tadalafil is approved by the US Food and Drug Administration (FDA) for treatment of signs and symptoms of BPH. Other PDE-5 inhibitors (eg, sildenafil, vardenafil) that are not FDA-approved for this use may also improve BPH symptoms. Do not prescribe in men who take nitrate therapy. In patients taking alpha-1-receptor antagonists or other drugs that lower blood pressure, additive hypotensive effects may be observed.</p>
<p>¶ Generally used for prevention of BPH progression; treatment for 6 to 12 months is typically needed for symptom improvement.</p>
<p>Δ A post-void residual (PVR) should be measured prior to initiating treatment; not recommended for use with elevated PVR (eg, &gt;300 mL).</p>
◊ Branded product no longer available.</div><div class="graphic_reference">Data from: Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</div><div id="graphicVersion">Graphic 129671 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
